

March 2005 PBAC OUTCOMES - Deferrals

DRUG AND FORM	DRUG USE AND TYPE	LISTING REQUESTED BY SPONSOR	PBAC OUTCOME AND COMMENT
<p>LETROZOLE tablet 2.5 mg, Femara®</p> <p>Novartis Pharmaceuticals Australia Pty Ltd</p> <p>Major submission</p>	<p>Antineoplastic agent</p>	<p>Extend the restricted benefit listing for treatment of early-stage hormone-dependent breast cancer in post-menopausal women who have completed standard adjuvant tamoxifen therapy.</p>	<p>The PBAC deferred the submission to seek clarification of the incremental cost-effectiveness ratios based on distant recurrence alone.</p>
		<p>Sponsor's comments</p>	<p>The sponsor will be responding to the PBAC request and refers you to its own website for further information. Weblink: http://www.novartis.com.au</p>
<p>PIOGLITAZONE tablet 15 mg, 30 mg and 45 mg, Actos®</p> <p>Eli Lilly Australia Pty Ltd</p> <p>Minor submission</p>	<p>Antidiabetic drug</p>	<p>For the treatment of type 2 diabetes in indigenous Australians. Unrestricted listing for this patient group</p>	<p>The PBAC deferred consideration of this matter until a formal process for provision of pharmaceuticals to the indigenous population under the 2004-05 Budget measure has been determined by the Department.</p>
		<p>Sponsor's comments</p>	<p>The sponsor needs to clarify this decision with the PBAC.</p>
<p>ROSIGLITAZONE tablet, 4 mg and 8 mg, Avandia®</p> <p>GlaxoSmithKline Australia Pty Ltd</p> <p>Minor submission</p>	<p>Antidiabetic drug</p>	<p>For the treatment of type 2 diabetes in indigenous Australians. Unrestricted listing for this patient group</p>	<p>The PBAC deferred consideration of this matter until a formal process for provision of pharmaceuticals to the indigenous population under the 2004-05 Budget measure has been determined by the Department.</p>

		Sponsor's comments	The sponsor has no comment
--	--	--------------------	----------------------------